Drugs / DPT-IPV-Hib-High
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02992925 | Nov 2016 → Dec 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPT-IPV-Hib-High | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02992925 ↗ |
| Modality | Vaccine | “Combined Vaccine” NCT02992925 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT02992925 ↗ |